EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bio-Techne's enterprise value is $10,560 Mil.
Bio-Techne's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,145 Mil. Therefore, Bio-Techne's EV-to-Revenue for today is 9.22.
The historical rank and industry rank for Bio-Techne's EV-to-Revenue or its related term are showing as below:
TECH'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6.74 Med: 9.9 Max: 23.95
Current: 9.22
During the past 13 years, the highest EV-to-Revenue of Bio-Techne was 23.95. The lowest was 6.74. And the median was 9.90.
TECH's EV-to-Revenue is ranked worse than 53.54% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs TECH: 9.22
As of today (2024-05-01), Bio-Techne's stock price is $63.21.
Bio-Techne's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.09. Therefore, Bio-Techne's PS Ratio for today is 8.91.
Bio-Techne EV-to-Revenue Historical Data
The historical data trend for Bio-Techne's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Techne's EV-to-Revenue
For the Biotechnology subindustry, Bio-Techne's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Bio-Techne's EV-to-Revenue falls into.
Bio-Techne's current Enterprise Value is $10,560 Mil.
Bio-Techne's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne's share price for today is $63.21.
Bio-Techne's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Bio-Techne's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 